Literature DB >> 12846581

Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment.

R W Berry1, A Abraha, S Lagalwar, N LaPointe, T C Gamblin, V L Cryns, L I Binder.   

Abstract

Abnormal aggregation of the microtubule-associated protein, tau, occurs in many neurodegenerative diseases, making it important to understand the mechanisms of tau polymerization. Previous work has indicated that the C-terminal region of tau inhibits polymerization in vitro, and a growing body of evidence implicates caspase cleavage of tau at Asp 421 in the C-terminus as an important inducer of tau polymerization in Alzheimer's disease. In the present study, we provide evidence that the C-terminal peptide fragment produced by caspase cleavage inhibits tau polymerization, suggesting that caspase cleavage of tau enhances its polymerization by removing the inhibitory control element. Moreover, we provide evidence that the peptide assumes an alpha-helical configuration and inhibits tau assembly by interacting with residues 321-375 in the microtubule binding repeat region. These findings indicate that formation of the fibrillar pathologies during the course of Alzheimer's disease may be driven or sustained by apoptotic events leading to caspase activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846581     DOI: 10.1021/bi027348m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  47 in total

Review 1.  Caspase-mediated degeneration in Alzheimer's disease.

Authors:  David H Cribbs; Wayne W Poon; Robert A Rissman; Mathew Blurton-Jones
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

2.  Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms.

Authors:  Benjamin Combs; Kellen Voss; T Chris Gamblin
Journal:  Biochemistry       Date:  2011-10-17       Impact factor: 3.162

3.  Alzheimer disease: caspases first.

Authors:  Jesús Avila
Journal:  Nat Rev Neurol       Date:  2010-11       Impact factor: 42.937

Review 4.  14-3-3/Tau Interaction and Tau Amyloidogenesis.

Authors:  Yuwen Chen; Xingyu Chen; Zhiyang Yao; Yuqi Shi; Junwen Xiong; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  J Mol Neurosci       Date:  2019-05-06       Impact factor: 3.444

Review 5.  Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease.

Authors:  Zhao Zhong Chong; Faqi Li; Kenneth Maiese
Journal:  Brain Res Brain Res Rev       Date:  2005-01-08

6.  Rho-kinase ROCK inhibitors reduce oligomeric tau protein.

Authors:  Tadanori Hamano; Norimichi Shirafuji; Shu-Hui Yen; Hirotaka Yoshida; Nicholas M Kanaan; Kouji Hayashi; Masamichi Ikawa; Osamu Yamamura; Youshi Fujita; Masaru Kuriyama; Yasunari Nakamoto
Journal:  Neurobiol Aging       Date:  2019-12-16       Impact factor: 4.673

7.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

8.  Pre-assembled tau filaments phosphorylated by GSK-3b form large tangle-like structures.

Authors:  Carolyn A Rankin; Qian Sun; T Chris Gamblin
Journal:  Neurobiol Dis       Date:  2008-07-16       Impact factor: 5.996

9.  Apoptosis in transgenic mice expressing the P301L mutated form of human tau.

Authors:  Rita M Ramalho; Ricardo J S Viana; Rui E Castro; Clifford J Steer; Walter C Low; Cecília M P Rodrigues
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

Review 10.  Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Authors:  Jacqueline R Kulbe; Edward D Hall
Journal:  Prog Neurobiol       Date:  2017-08-26       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.